secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0000950170-22-026337
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Chief Business & Legal Officer Joseph Vittiglio resigns; COO Marc Blaustein gets retention bonus and expanded role
--------------------------------------------------------------------------------

- Joseph Vittiglio resigns as Chief Business and Legal Officer & Secretary, effective Dec 31, 2022.
- COO Marc Blaustein assumes business development and investor relations responsibilities after Vittiglio's departure.
- Blaustein receives a service-based cash bonus of $83,000, payable in two equal installments (Dec 2022, June 2023).
- Blaustein eligible for performance-based cash bonuses up to $332,000 tied to critical corporate objectives set by Compensation Committee.
- Service-based bonus repayment required if Blaustein leaves voluntarily (non-Good Reason) or is terminated for Cause before May 31, 2023 (first installment) or Dec 31, 2023 (second).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/0000950170-22-026337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022026337/fnch-20221212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer